ClinicalTrials.gg
RecruitingNCT07651826Updated Jun 16, 2026

Immiseal™ Dural Sealant Post-Market Registry Study

An observational study in Dural Defect, Cerebrospinal Fluid Leak and Neurosurgical Procedures, sponsored by Medprin Regenerative Medical Technologies Co., Ltd.. Recruiting at 1 site in Latvia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Medprin Regenerative Medical Technologies Co., Ltd. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
85
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicentre, prospective, open-label, single-arm, observational, post-market clinical follow-up registry study designed to observe the safety and performance of the Immiseal™ Dural Sealant System when used as an adjunct to standard methods of dural repair to provide watertight closure during neurosurgical procedures. Eligible adult subjects requiring dural repair after neurosurgical procedures or traumatic injury, for whom the investigator has made the clinical decision to use the device, will be enrolled and followed for approximately 100 ± 10 days after surgery.

02

Conditions studied

  • Dural Defect
  • Cerebrospinal Fluid Leak
  • Neurosurgical Procedures

Keywords

  • Immiseal
  • Dural sealant
  • Dural repair
  • Cerebrospinal Fluid Leak
  • Surgical site infection
  • Post-market clinical follow-up
  • Dural Defect
  • Neurosurgical Procedure
03

In context

Cerebrospinal Fluid Leak

41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.

This study's planned enrollment of 85 is below the median of 96 across 14 observational studies indexed under Cerebrospinal Fluid Leak.

Browse Cerebrospinal Fluid Leak studies →

Lead sponsor

Medprin Regenerative Medical Technologies Co., Ltd. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients aged 18 to 75 years who require dural repair following neurosurgical procedures or traumatic injury and for whom the investigator has made the clinical decision to use the Immiseal™ Dural Sealant System as an adjunct to standard methods of dural repair. Eligible patients may have dural defects associated with craniocerebral trauma, brain tumour, cerebrovascular disease, congenital disease of the nervous system, posterior fossa surgery, spinal canal disease, or other neurosurgical procedures or accidents, and may present with or be at risk of cerebrospinal fluid leakage requiring auxiliary dural repair.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years old, regardless of gender.
  2. Patients diagnosed with craniocerebral trauma, brain tumour, cerebrovascular disease, congenital disease of the nervous system, or spinal canal disease, who undergo neurosurgical procedures such as posterior fossa surgery or other interventions resulting in dural defects, whether due to surgery or accidental injury, and who present with, or are at risk of, cerebrospinal fluid (CSF) leakage requiring auxiliary dural repair.
  3. Patients willing to comply with the requirements of the clinical investigation by signing the .
  4. Female patients of must use highly effective methods for the duration of the study. Highly effective contraceptive methods include hormonal contraception, intrauterine device, or sexual abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Immiseal™ Dural Sealant System is not to be used in confined bone structures where nerves are present, since neural compression may result due to hydrogel swelling.
  2. Patients with an active infection present at the surgical site.
  3. Patients with less than 3 months.
  4. Female patients who are pregnant, planning pregnancy, breastfeeding, and/or unwilling to use adequate during the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
85 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients Receiving Immiseal™ Dural Sealant System

    Adult patients requiring dural repair following neurosurgical procedures or traumatic injury, for whom the investigator has made the clinical decision to use the Immiseal™ Dural Sealant System as an adjunct to standard methods of dural repair. Subjects will be followed for safety and device performance outcomes through approximately 100 ± 10 days post-operation.

06

What researchers measure

Primary outcomes

  1. Rate of Central Nervous System (CNS) Infection

    Percentage of subjects with central nervous system infection up to 30 days post-operation, including bacterial meningitis, aseptic meningitis, and/or surgical site infection.

    Time frame: Up to 30 days post-operation

Secondary outcomes

  1. Cerebrospinal Fluid (CSF) Leak Rate

    Percentage of subjects with cerebrospinal fluid leak after primary dural repair using the Immiseal™ Dural Sealant System, used to assess effective watertight dural closure.

    Time frame: Up to 100 ± 10 days post-operation

Other outcomes

  1. Meningitis Rate and Surgical Site Infection Rate Over the Study Period

    Meningitis rate and surgical site infection rate will be observed over the course of the study. The analysis will be performed using Kaplan-Meier survival analysis over the whole follow-up period.

    Time frame: Up to 100 ± 10 days post-operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Aug 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 16, 2026
StartActual
Feb 17, 2026
Primary completionEst.
Aug 15, 2026
CompletionEst.
Nov 23, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07651826
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Feb 17, 2026
Primary completion
Aug 15, 2026 (estimated)
Completion
Nov 23, 2026 (estimated)
Last update
Jun 16, 2026

Study contacts

Yuchuan Zhang
Contact
zhangyuchuan@medprin.com
+86 20 32296118
Xiaoting Liao
Contact
liaoxiaoting@medprin.com
+86 15602300416

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion